Vanda Pharmaceuticals Inc. (LON:0LKB)

Market Cap	265.53M +27.5%
Revenue (ttm)	160.57M +8.7%
Net Income	-163.81M
EPS	-2.78
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	28,083
Average Volume	11,157
Open	7.50
Previous Close	7.46
Day's Range	7.16 - 7.68
52-Week Range	3.83 - 9.60
Beta	0.61
RSI	47.21
Earnings Date	Feb 11, 2026

About Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s commercial portfolio includes Fanapt for the acute treatment of manic or mixed episodes associated with bipolar I disorder and the treatment of schizophrenia; HETLIOZ to treat non-24-hour sleep-wake disorders and nighttime sleep disturbances; PONVORY to treat relapsing forms of multiple sclerosis; and NEREUSTM for preventing vomiting induced by motion. It also develop...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2002
• Employees: 368
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0LKB

Financial Performance

In 2025, Vanda Pharmaceuticals's revenue was $216.11 million, an increase of 8.72% compared to the previous year's $198.77 million. Losses were -$220.47 million, 1066.5% more than in 2024.

Financial numbers in USD